Search Results - giorgio+raimondi

4 Results

Sort By:

Immunotherapy delivery system to improve organ transplantation outcomes

Value PropositionNovel Therapy: Hydro(LNp), is a new therapeutic application that will improve outcomes for organ transplant recipients. Convenient Delivery: Hydro(LNp) is a two-phase delivery system that increases effectiveness in regulating transplant rejection.Broad Scope: Has the potential to adapt for applications beyond transplantation, involving...

Published: 3/14/2025 | Inventor(s): Giorgio Raimondi, Joel Schneider, Julia Patrone, Alexander Komin, Monessha Nambiar, Xiomara Calderon-Colon, Olivia Tiburzi

Keywords(s):

Category(s): Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms

Peptide Hydrogels for Delivery of Immunosuppressive Drugs and Uses Thereof

Unmet NeedMore than 1 million tissue transplantations are performed each year. Organ transplantation therapies are typically combined with immunosuppressive agents to reduce the risk of allograft rejection and to enhance transplant survival. However, current immunosuppressive drugs are administered systemically and have several dose-limiting side effects...

Published: 3/14/2025 | Inventor(s): Giorgio Raimondi, Joel Schneider, Poulami Majumder

Keywords(s): Disease Indication, Drug Delivery Vehicle, Hydrogel, Inflammatory Disorders, Therapeutic Matter, Therapeutics, Tissue/organ transplant rejection

Category(s): Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms

Engineered Tolerogenic Artificial Antigen-presenting Cells for Specific Expansion of Regulatory T Cells

Unmet NeedGlobal incidence of autoimmune disease is on the rise, and currently one in twelve Americans (including one in 9 women) suffer from autoimmune disease. Particularly, Type 1 Diabetes (T1D) represents a highly prevalent autoimmune disease, affecting over 20 million people. These diseases occur when the body’s immune system incorrectly attacks...

Published: 3/14/2025 | Inventor(s): Jordan Green, Jamie Spangler, Stephany Tzeng, Kelly Rhodes, Giorgio Raimondi, Marcos Iglesias Lozano, Jakub Tomala, Derek VanDyke, Randall Meyer

Keywords(s): Autoimmune Diseases, Biologics, Discovery/Research Tools, Disease Indication, Drug Delivery Vehicle, Inflammatory Disorders, Polymers, Recombinant Proteins, Research Reagent, Therapeutic Matter, Therapeutic Substance, Therapeutics, Transplants

Category(s): Clinical and Disease Specializations > Autoimmunity, Clinical and Disease Specializations > Transplantation, Clinical and Disease Specializations > Diabetes > Type 1 Diabetes, Technology Classifications > Therapeutic Modalities > Immunotherapies, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Technology Classifications > Research Tools, Technology Classifications > Therapeutic Modalities > Cell Therapies

Lipid Nanoparticles as Oral Vehicles of Immunotherapy

Unmet NeedType 1 diabetes (T1D) affects 1.25 million Americans currently and by 2050, this number is expected to reach 5 million. Though a currently untreatable autoimmune disease, one of the more promising approaches has been a costimulatory blockade of malfunctioning immune cells via administration of CTLA4-Ig. However, its efficacy is impeded by...

Published: 3/14/2025 | Inventor(s): Giorgio Raimondi, Julia Patrone, Xiomara Calderon-Colon, Olivia Tiburzi

Keywords(s): Diabetes, Disease Indication, Drug Delivery Mechanism, Drug Delivery Vehicle, Immunotherapy, Metabolic Disorders, Nanoparticles, Oral Administration, Single, Therapeutic Matter, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations > Diabetes > Type 1 Diabetes, Clinical and Disease Specializations > Diabetes, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms